Sun Pharma wins patent case against Eli Lily over cancer drug

New Delhi: Sun Pharma today claimed victory over Eli Lily and Co in a patent litigation over Gemzar, used in cancer treatment, with a US federal court ruling in its favour, reports PTI. 

Eli Lily had contended that an abbreviated new drug application (ANDA) by Sun infringed its patent on the active ingredient used in Gemzar.
 
"The US Court of Appeals for the Federal Circuit affirmed the judgement of the US District Court for the Eastern District of Michigan against Eli Lily and Co finding certain claims of US Patent No 5,464,826 (826 patent) invalid," Sun said in a statement.
 
In the Michigan lawsuit, Eli Lilly had contented that Sun Pharma's ANDA infringed certain claims from the 826 patent and US Patent No 4,808,614 (614 patent) that described gemcitabine and its uses—the active ingredient in Gemzar.
 
Earlier the Michigan District Court had ruled against Eli Lily stating that the asserted claims of the 826 patent are invalid for obviousness-type double patenting over US Patent No 4,808,614 (614 patent), Sun said.
 
The Appeals Court agreed with the ruling of the District Court and noted that the Michigan Court had correctly followed the Federal Circuit's precedent regarding double patenting.
 
Sun said the federal court has ruled Eli Lily's patent invalid, that would have expired on November 7, 2012, and would have had paediatric exclusivity through 7 May, 2013.
 
It, however, said that another patent '614', not part of the appeal, expired on 15 May, 2010, but has paediatric exclusivity through 15 November, 2010.

User

What's Not

Cement stocks are losing sheen with the onset of monsoon rains. Andhra Cements, Ultratech (down...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation
Bulk Deals

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)